ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.15
1.17%
US Tech 100
18,118.80
1.58%
다우존스 지수
39,908.00
0.88%
Bitcoin
66,128.70
7.44%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) 뉴스

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NBIX
일자시간출처헤드라인심볼기업
2024/05/1505:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/1505:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/1421:30PR Newswire (US)Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0922:45PR Newswire (US)Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0921:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0905:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0821:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0805:15PR Newswire (US)Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0721:30PR Newswire (US)Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0621:30PR Newswire (US)Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0402:15PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0120:00PR Newswire (US)Neurocrine Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/0106:12PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/04/2421:30PR Newswire (US)Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia CommunityNASDAQ:NBIXNeurocrine Biosciences Inc
2024/04/2320:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
2024/04/1705:01GlobeNewswire Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/04/1105:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/04/0321:30PR Newswire (US)Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/2821:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/1205:01PR Newswire (US)Neurocrine Biosciences to Participate at Virtual Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/0906:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/0906:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/0109:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/0108:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/03/0108:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/02/2806:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/02/2806:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
2024/02/2307:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/02/2106:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/02/1607:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 검색 관련기사 보기:NASDAQ:NBIX

최근 히스토리

NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
FX
USDGBP
US Dollar vs Sterling
USOTC
BNPQY
BNP Paribas (QX)
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
NASDAQ
MSFT
Microsoft
COIN
ETHUSD
Ethereum
NYSE
XOM
Exxon Mobil
AMEX
SPY
SPDR S&P 500
COIN
SOLUSD
Solana
NASDAQ
GOOGL
Alphabet
CCOM
SILVER
SILVER
FX
USDEUR
US Dollar vs Euro
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유